Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1989 1
1992 1
1996 1
1997 1
1998 1
1999 3
2000 3
2002 2
2003 3
2004 2
2005 1
2006 3
2007 2
2008 1
2009 1
2010 1
2011 1
2012 5
2013 2
2014 1
2015 8
2016 5
2017 3
2018 5
2019 6
2020 6
2021 1
2022 4
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
High-carb or low-carb, that is a question.
Igawa H, Takamura T. Igawa H, et al. Diabetol Int. 2016 Nov 11;8(1):1-3. doi: 10.1007/s13340-016-0296-5. eCollection 2017 Mar. Diabetol Int. 2016. PMID: 30603299 Free PMC article. No abstract available.
Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.
Sampei Z, Koo CX, Teo FJ, Toh YX, Fukuzawa T, Gan SW, Nambu T, Ho A, Honda K, Igawa T, Ahmed F, Wang CI, Fink K, Nezu J. Sampei Z, et al. Among authors: igawa t. Antibodies (Basel). 2023 May 15;12(2):36. doi: 10.3390/antib12020036. Antibodies (Basel). 2023. PMID: 37218902 Free PMC article.
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, Asanuma K, Funaki M, Ichiki M, Ikuta Y, Ito S, Joyashiki E, Komatsu SI, Muto A, Nishimura K, Okuda M, Sanada H, Sato M, Shibahara N, Wakabayashi T, Yamaguchi K, Matsusaki A, Sampei Z, Shiraiwa H, Konishi H, Kawabe Y, Hattori K, Kitazawa T, Igawa T. Teranishi-Ikawa Y, et al. Among authors: igawa t. J Thromb Haemost. 2024 Feb;22(2):430-440. doi: 10.1016/j.jtha.2023.09.034. Epub 2023 Nov 6. J Thromb Haemost. 2024. PMID: 37940048 Free article.
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K. Nishio M, et al. Among authors: igawa y. Transl Lung Cancer Res. 2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13. Transl Lung Cancer Res. 2023. PMID: 37425411 Free PMC article.
A Computational Physics-based Approach to Predict Unbound Brain-to-Plasma Partition Coefficient, K(p,uu).
Lawrenz M, Svensson M, Kato M, Dingley KH, Chief Elk J, Nie Z, Zou Y, Kaplan Z, Lagiakos HR, Igawa H, Therrien E. Lawrenz M, et al. Among authors: igawa h. J Chem Inf Model. 2023 Jun 26;63(12):3786-3798. doi: 10.1021/acs.jcim.3c00150. Epub 2023 Jun 2. J Chem Inf Model. 2023. PMID: 37267072
Optimal brain penetration of small-molecule central nervous system (CNS) drugs is characterized by a high unbound brain/plasma ratio (K(p,uu)). While various medicinal chemistry strategies and in silico models have been reported to improve BBB penetration, they have limite …
Optimal brain penetration of small-molecule central nervous system (CNS) drugs is characterized by a high unbound brain/plasma ratio (K …
New oral anticoagulants for atrial fibrillation: a review of clinical trials.
O'Dell KM, Igawa D, Hsin J. O'Dell KM, et al. Among authors: igawa d. Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Clin Ther. 2012. PMID: 22417716 Review.
From the intention-to-treat analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, rivaroxaban was reported to be noninferior to warfar …
From the intention-to-treat analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonis …
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K. Yamaguchi O, et al. Among authors: igawa s. Thorac Cancer. 2024 Jan;15(2):163-171. doi: 10.1111/1759-7714.15173. Epub 2023 Nov 27. Thorac Cancer. 2024. PMID: 38013668 Free PMC article.
78 results